MATTHEW LINDQUIST: Open Payments
NPI 1710969159 · ST. LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 7 payments from 5 companies in 2025. Trend: 2023 $9,427 · 2024 $11,239 · 2025 $471
Food & beverage: $471
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $121 |
| Alkermes, Inc. | 2 | $104 |
| AstraZeneca Pharmaceuticals LP | 1 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
Products named: REXULTI, COBENFY, ARISTADA, CAPLYTA.
Industry payments across MO — which companies pay providers there.
